A Phase 2 interventional study of Trastuzumab and Pertuzumab in Neoplasms, Solid Tumors and Biliary Cancer, sponsored by Genentech, Inc.. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-23.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Urinary Bladder Neoplasms · Hoffmann-La Roche.
Among the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 2, and was the 1st registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →None of the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche is open now. The open studies under Urinary Bladder Neoplasms, anywhere →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 3
First in 2014; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 673 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 292 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
This study's enrollment of 673 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Browse Urinary Bladder Neoplasms studies →Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Compared within Urinary Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
General Inclusion Criteria:
Study-Drug Specific Inclusion Criteria:
Trastuzumab plus Pertuzumab
Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer
a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)
Erlotinib
Vemurafenib plus Cobimetinib
Vismodegib
Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating hedgehog pathway relevant mutation (activating mutation of smoothened [SMO] or loss-of-function mutation of protein patched homolog-1 [PTCH-1])
a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)
Alectinib
Atezolizumab
General Exclusion Criteria:
Study-Drug Specific Exclusion Criteria:
Trastuzumab plus Pertuzumab
Erlotinib
Vemurafenib plus Cobimetinib
Vismodegib
Alectinib
Atezolizumab
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
Drug: Trastuzumab · Drug: Pertuzumab
Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
Drug: Atezolizumab
Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.
Drug: Vemurafenib
Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
Drug: Vemurafenib · Drug: Cobimetinib
Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.
Drug: Vismodegib
Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
Drug: Alectinib
Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.
Drug: Erlotinib
Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Herceptin
Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Perjeta
Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Tarceva
Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Zelboraf
Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Cotellic
Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Erivedge
Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Alecensa
Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Also known as: Tecentriq
Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator
The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.
Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)
Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)
The Objective Response Rate (ORR) is defined as the proportion of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)
Percentage of Participants With Disease Control
Disease Control Rate (DCR) is defined as the proportion of patients whose best response is CR, PR or stable disease maintained more than 4 months (SD\>4 months). Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.
Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)
Progression-Free Survival (PFS)
PFS is defined as the time from the start of study treatment to the first occurrence of disease progression, or death, whichever occurs first. Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.
Time frame: From the date of first study treatment until disease progression as assessed by the investigator, or death from any cause, whichever occurs first (72.1 months)
Overall Survival (OS)
Overall Survival (OS, months) is defined as the time from the date of the first study treatment (Day 1) to the date of death from any cause.
Time frame: 87.5 months
Duration of Response (DoR)
Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) to date of first occurrence of disease progression as determined by the investigator, or death from any cause, whichever occurs first.
Time frame: From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (70.8 months)
Number of Participants With Adverse Events
Incidence, nature, and severity of Adverse Events (AE), per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) for participants enrolled prior to Version 6 of the protocol. The NCI CTCAE (v5.0) grading scale was used for assessing AE severity for participants enrolled under Version 6 of the protocol and subsequent versions.
Time frame: From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years)
| Milestone | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Started | 357 | 175 | 55 | 15 | 37 | 21 | 13 |
| Completed | 28 | 24 | 3 | 0 | 3 | 0 | 0 |
| Not completed | 329 | 151 | 52 | 15 | 34 | 21 | 13 |
| Withdrew: Death | 280 | 118 | 46 | 13 | 31 | 16 | 12 |
| Withdrew: Withdrawal by subject | 21 | 13 | 3 | 2 | 2 | 3 | 0 |
| Withdrew: Lost to follow-up | 21 | 5 | 1 | 0 | 1 | 2 | 0 |
| Withdrew: Reason not specified | 6 | 5 | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Study ended by sponsor | 1 | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew informed consent before receiving study drug | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.
| Percentage of Participants | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator | 21.0 (16.9 to 25.6) | 19.5 (13.9 to 26.2) | 25.5 (14.7 to 39.0) | 33.3 (11.8 to 61.6) | 10.8 (3.0 to 25.4) | 14.3 (3.0 to 36.3) | 7.7 (0.2 to 36.0) |
The Objective Response Rate (ORR) is defined as the proportion of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Percentage of Participants | Atezolizumab |
|---|---|
| Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC) | 29.5 (16.8 to 45.2) |
Disease Control Rate (DCR) is defined as the proportion of patients whose best response is CR, PR or stable disease maintained more than 4 months (SD\>4 months). Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.
| Percentage of Participants | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Disease Control | 41.5 (36.3 to 46.8) | 39.1 (31.8 to 46.8) | 34.5 (22.2 to 48.6) | 66.7 (38.4 to 88.2) | 16.2 (6.2 to 32.0) | 42.9 (21.8 to 66.0) | 23.1 (5.0 to 53.8) |
PFS is defined as the time from the start of study treatment to the first occurrence of disease progression, or death, whichever occurs first. Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.
| Months | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | 2.8 (2.7 to 3.4) | 2.7 (1.6 to 3.0) | 3.1 (1.8 to 5.5) | 8.2 (3.9 to 19.5) | 1.8 (1.6 to 1.8) | 3.2 (1.7 to 6.6) | 1.8 (1.0 to 8.8) |
Overall Survival (OS, months) is defined as the time from the date of the first study treatment (Day 1) to the date of death from any cause.
| Months | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 10.1 (8.7 to 11.7) | 13.5 (11.2 to 17.4) | 10.6 (5.2 to 13.5) | 15.6 (6.8 to 27.9) | 9.8 (4.0 to 13.4) | 14.1 (8.7 to 25.6) | 7.7 (2.2 to 15.0) |
Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) to date of first occurrence of disease progression as determined by the investigator, or death from any cause, whichever occurs first.
| Months | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Duration of Response (DoR) | 7.3 (5.8 to 9.3) | 32.1 (6.9 to NA) | 6.0 (3.7 to 11.1) | 17.2 (7.4 to NA) | 14.1 (6.5 to NA) | 6.6 (6.0 to NA) | 8.3 (NA to NA) |
Incidence, nature, and severity of Adverse Events (AE), per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) for participants enrolled prior to Version 6 of the protocol. The NCI CTCAE (v5.0) grading scale was used for assessing AE severity for participants enrolled under Version 6 of the protocol and subsequent versions.
| Participants | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| With at least one AE | 334 | 162 | 54 | 15 | 35 | 21 | 12 |
| With at least one SAE | 95 | 62 | 21 | 11 | 13 | 7 | 3 |
| With at least one Grade 3-5 AE | 146 | 97 | 37 | 12 | 21 | 11 | 4 |
| With at least one Related AE | 261 | 104 | 49 | 13 | 26 | 19 | 9 |
| With at least one Related SAE | 17 | 14 | 6 | 5 | 2 | 1 | 0 |
| With at least one Grade 3-5 related AE | 43 | 25 | 25 | 6 | 8 | 4 | 1 |
| With at least one non-serious AESI | 5 | 9 | 3 | 3 | 0 | 0 | 0 |
| With at least one AE leading to study drug withdrawn | 17 | 15 | 10 | 3 | 1 | 0 | 1 |
| With at least one AE leading to study drug interruption | 79 | 45 | 27 | 11 | 11 | 6 | 4 |
| With at least one AE leading to study drug reduction | 3 | 1 | 28 | 3 | 0 | 4 | 0 |
| With at least one AE leading to death | 13 | 5 | 2 | 2 | 1 | 0 | 1 |
Collected over In the AE section, AE timeframe was from first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Plus Pertuzumab | 285/357 (79.8%) | 95/357 (26.6%) | 313/357 (87.7%) |
| Atezolizumab | 118/174 (67.8%) | 62/174 (35.6%) | 147/174 (84.5%) |
| Vemurafenib | 46/55 (83.6%) | 21/55 (38.2%) | 50/55 (90.9%) |
| Vemurafenib Plus Cobimetinib | 13/15 (86.7%) | 11/15 (73.3%) | 12/15 (80%) |
| Vismodegib | 31/37 (83.8%) | 13/37 (35.1%) | 30/37 (81.1%) |
| Alectinib | 16/21 (76.2%) | 7/21 (33.3%) | 20/21 (95.2%) |
| Erlotinib | 12/13 (92.3%) | 3/13 (23.1%) | 11/13 (84.6%) |
| Event | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 6/357 | 3/174 | 0/55 | 3/15 | 2/37 | 0/21 | 1/13 |
| PyrexiaGeneral disorders | 1/357 | 2/174 | 1/55 | 2/15 | 0/37 | 0/21 | 0/13 |
| SepsisInfections and infestations | 5/357 | 4/174 | 1/55 | 2/15 | 1/37 | 0/21 | 0/13 |
| Ejection fraction decreasedInvestigations | 1/357 | 0/174 | 0/55 | 2/15 | 0/37 | 0/21 | 0/13 |
| PneumoniaInfections and infestations | 4/357 | 5/174 | 2/55 | 0/15 | 2/37 | 0/21 | 1/13 |
| FallInjury, poisoning and procedural complications | 2/357 | 1/174 | 0/55 | 0/15 | 0/37 | 0/21 | 1/13 |
| Confusional statePsychiatric disorders | 1/357 | 1/174 | 0/55 | 0/15 | 0/37 | 0/21 | 1/13 |
| Anaemia of malignant diseaseBlood and lymphatic system disorders | 0/357 | 0/174 | 0/55 | 1/15 | 0/37 | 0/21 | 0/13 |
| Cardiac failureCardiac disorders | 1/357 | 0/174 | 0/55 | 1/15 | 0/37 | 0/21 | 0/13 |
| Stress cardiomyopathyCardiac disorders | 0/357 | 0/174 | 0/55 | 1/15 | 0/37 | 0/21 | 0/13 |
| Event | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 80/357 | 40/174 | 21/55 | 8/15 | 8/37 | 6/21 | 4/13 |
| FatigueGeneral disorders | 105/357 | 46/174 | 29/55 | 7/15 | 14/37 | 7/21 | 5/13 |
| DiarrhoeaGastrointestinal disorders | 129/357 | 35/174 | 13/55 | 7/15 | 9/37 | 3/21 | 6/13 |
| Decreased appetiteMetabolism and nutrition disorders | 52/357 | 22/174 | 10/55 | 5/15 | 5/37 | 3/21 | 6/13 |
| VomitingGastrointestinal disorders | 47/357 | 26/174 | 13/55 | 6/15 | 2/37 | 1/21 | 1/13 |
| Oedema peripheralGeneral disorders | 26/357 | 14/174 | 5/55 | 6/15 | 6/37 | 7/21 | 0/13 |
| Abdominal painGastrointestinal disorders | 43/357 | 25/174 | 6/55 | 5/15 | 1/37 | 4/21 | 1/13 |
| ConstipationGastrointestinal disorders | 37/357 | 23/174 | 9/55 | 3/15 | 6/37 | 7/21 | 0/13 |
| PyrexiaGeneral disorders | 36/357 | 16/174 | 4/55 | 5/15 | 2/37 | 1/21 | 4/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 44/357 | 22/174 | 18/55 | 4/15 | 2/37 | 2/21 | 0/13 |
Baseline characteristics are provided for the safety population, which includes all participants who received at least one dose of study treatment. One participant who enrolled in the atezolizumab arm withdrew from the study before receiving any treatment and was therefore excluded.
| Age, Categorical(Participants) | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 201 | 77 | 32 | 6 | 15 | 11 | 6 | 348 |
| >=65 years | 156 | 97 | 23 | 9 | 22 | 10 | 7 | 324 |
| Age, Customized(Years) | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 61.0 ± 12.06 | 65.1 ± 12.33 | 61.3 ± 11.15 | 63.2 ± 8.69 | 63.5 ± 11.41 | 63.5 ± 12.17 | 64.5 ± 13.41 | 62.4 ± 12.08 |
| Sex: Female, Male(Participants) | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 179 | 98 | 29 | 7 | 16 | 12 | 5 | 346 |
| Male | 178 | 76 | 26 | 8 | 21 | 9 | 8 | 326 |
| Ethnicity (NIH/OMB)(Participants) | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 19 | 15 | 3 | 1 | 1 | 0 | 1 | 40 |
| Not Hispanic or Latino | 320 | 152 | 48 | 12 | 36 | 20 | 12 | 600 |
| Unknown or Not Reported | 18 | 7 | 4 | 2 | 0 | 1 | 0 | 32 |
| Race (NIH/OMB)(Participants) | Trastuzumab Plus Pertuzumab | Atezolizumab | Vemurafenib | Vemurafenib Plus Cobimetinib | Vismodegib | Alectinib | Erlotinib | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 7 |
| Asian | 21 | 11 | 1 | 0 | 3 | 0 | 1 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 28 | 20 | 7 | 1 | 2 | 2 | 0 | 60 |
| White | 288 | 131 | 46 | 13 | 31 | 18 | 10 | 537 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 16 | 8 | 1 | 1 | 1 | 1 | 1 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient-level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).
Ran from Apr 2014 to primary completion in May 2023, 109 months.
Results were first posted in Jul 2024, 1 year 1 month after primary completion.
Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 109 months is above that.
Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab · Pertuzumab · Erlotinib · Vemurafenib · Cobimetinib · HhAntag691 · Alectinib · Atezolizumab